High cost of cell therapies is one of the biggest challenges, with financial implications for patients, payers, and providers, and this is expected to hamper the market growth over the forecast period. For instance, in May 2022, chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) received the U.S. FDA approval for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).It costs around US$ 475,000 for a single infusion. This has resulted in limited adoption of such therapies, thus, hampering growth of the market. Moreover, in April 2022, Yescarta, a cell therapy, developed by Kite Pharma, Inc., a pharmaceutical company, was approved by the U.S. FDA for the treatment of certain B-cell lymphomas. The listed price for axicabtagene ciloleucel (Yescarta) in the U.S. is US$ 373,000.
Market Opportunity– Increasing Investments by Key Market Players
Increasing adoption of inorganic growth strategies such as investments is expected to drive growth of the global cell therapy manufacturing market. For instance, on February 6, 2024, AstraZeneca, a global pharmaceutical company, announced that it had invested US$ 300 million in a facility in Rockville, Maryland, U.S. for discovery and development of cell therapies. The aim of the investment is to launch its life-saving cell therapy platforms in the U.S. for critical cancer trials and future commercial supply.
Cell Therapy Manufacturing Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients